Literature DB >> 12965269

Interferon-alpha significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP.

Juan Feng1, Tatsuro Misu, Kazuo Fujihara, Hiroshi Saito, Toshiaki Takahashi, Takeshi Kohnosu, Yusei Shiga, Atsushi Takeda, Shigeru Sato, Sadao Takase, Yasuto Itoyama.   

Abstract

We, for the first time, analyzed T cell and natural killer (NK) cell subsets in the cerebrospinal fluid (CSF) in nine patients with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) treated with interferon-alpha (IFN-alpha). The CD4/CD8 ratio in CSF was significantly lower after the therapy, which is mainly attributable to the significant reduction in CD4+ cells, especially CD25+CD4 and CD45RO+CD4 cell subsets. Meanwhile, NK, natural T and NKT cell subsets in the CSF remained unchanged. There was no CSF lymphocyte subset significantly associated with the clinical efficacy of IFN-alpha in this small-scale study, and more patients should be analyzed to ascertain the link.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965269     DOI: 10.1016/s0165-5728(03)00219-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

1.  Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

Authors:  Reza Boostani; Rosita Vakili; Samane Sadat Hosseiny; Ali Shoeibi; Bahare Fazeli; Mohammad Mehdi Etemadi; Faeze Sabet; Narges Valizade; Seyed Abdolrahim Rezaee
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

2.  CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.

Authors:  Soraya Maria Menezes; Daniele Decanine; David Brassat; Ricardo Khouri; Saul V Schnitman; Ramon Kruschewsky; Giovanni López; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Anne-Mieke Vandamme; Bernardo Galvão-Castro; Roland Liblau; Johan Van Weyenbergh
Journal:  J Neuroinflammation       Date:  2014-01-29       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.